The main driver of the past two weeks remains the growing dollar index, which...
Regeneron Pharmaceuticals: Strength in Science
In 2021, Regeneron Pharmaceuticals attracted the active attention of investors with its victories in the anti-cancer struggle. Now Regeneron Pharmaceuticals no longer sells its famous anti-coronavirus “cocktail” REGEN-COV, but retains the same strong market position.
In January of this year, the FDA in the United States suspended the license for the use of REGEN-COV in the treatment of the Omicron strain, as it recognized it as ineffective. In other cases, this would have led to the collapse of securities, but not here – long before covid, Regeneron had a strong market position with its seven popular drugs.
The strengths of Regeneron’s business in the second quarter of 2022:
Overall, the business looks perfectly balanced and stable.
Even when the coronavirus begins to recede, Regeneron will focus on other drugs.
The consensus forecast for Regeneron Pharmaceuticals paper is $780.
The MACD indicator on the daily chart is declining in the positive zone, but the buy signal remains in force. The Stochastic oscillator falls into the negative zone and signals a sale. Technical signals on the daily chart look mixed due to market conditions.